Overexpression of key complement regulators in glioblastoma.

Overview

Authors: Linnea Blomberg¹, Leonora Raba¹, Johan Bengzon², Kurt Osther¹, Henrietta Nittby Redebrandt^1,2

ORCID iDs: Henrietta Nittby Redebrandt

Division of Clinical Sciences, Department of Neurosurgery, Rausing Laboratory, Lund University, Lund, Sweden
Department of Neurosurgery, Skåne University Hospital, Lund, Sweden

Institutions: Lund University (Sweden); Skåne University Hospital (Sweden)

Journal: PloS one, volume 21, issue 5, article e0349101

Dates: received 30 September 2025; accepted 24 April 2026; published online 15 May 2026

Type: Research article · Language: English

License: CC BY

Identifiers: DOI 10.1371/journal.pone.0349101 · PMID 42139305 · PMCID PMC13178988 · OpenAlex W7161258882

Open access: gold, a free copy (OpenAlex)

Status: data only (how the code is found and verified)

Categories: genetics / omics (modality), human (organism), rat (organism), other condition (population), cellular / molecular (subfield)

Methods: Spectral & time-frequency, Statistics, Evoked potentials

MeSH: Brain Neoplasms*, Complement System Proteins*, Gene Expression Regulation, Neoplastic*, Glioblastoma*, Animals, C-Reactive Protein, Cell Line, Tumor, Complement C1 Inhibitor Protein, Complement Factor H, Gene Expression Profiling, Humans, Nerve Tissue Proteins, Pentraxins, Rats, Serum Amyloid P-Component (* major topic)

Topic: Biomarkers in Disease Mechanisms (Immunology, Immunology and Microbiology), according to OpenAlex

Funding: Cancerfonden (25 4458 Pj, 22 2100 Pj 01 H); Region Skåne (ALF Young Researcher)

Citations: cited by 1 paper (Europe PMC); 71 references in the paper

Abstract

Background: Glioblastoma (GBM) is the most prevalent and malignant primary brain tumor in adults. While immune evasion is a well-recognized driver of GBM progression and a major obstacle for efficient immunotherapy, the role of the complement system remains underexplored. C1-inhibitor (C1-INH), a regulator of complement activation, was recently found overexpressed in GBM. We therefore hypothesized that GBM overexpresses additional complement regulators beyond C1-INH and the present work aimed to identify these.

Method: Gene expression of complement inhibitors, the complement regulator pentraxin-3 (PTX3), and complement proteins was analyzed across nine publicly available transcriptomic datasets. Within each dataset, statistical comparisons were performed between sample groups for each gene. Differentially expressed complement inhibitors were validated at the protein level by immunostaining in the rat GBM cell line NS1 and patient derived GBM tissue.

Results: CFI, encoding factor I, was significantly overexpressed in GBM compared to non-tumoral brain, while THBD and CFH, encoding thrombomodulin and factor H, displayed moderate overexpression. SERPING1, encoding C1-INH, was also upregulated, confirming previous findings. Immunostaining confirmed the expression of these inhibitors in vitro as well as in human glioblastoma tissue. Additionally, PTX3 and early complement proteins were significantly overexpressed in GBM, while levels of C5 and downstream components were comparable to normal brain.

Conclusions: Our findings indicate that the GBM tumor overexpresses a specific set of complement regulators and components of the complement cascade, possibly inhibiting an efficient anti-tumoral immune response. Further investigations of these regulators as potential therapeutical targets in GBM are therefore highly warranted.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

geo:GSE263588, at NCBI GEO; found in the references

Data Availability

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 15 MeSH terms, 2 funders, 62 references.

Cite

This paper

Blomberg, L., Raba, L., Bengzon, J., Osther, K., & Nittby Redebrandt, H. (2026). Overexpression of key complement regulators in glioblastoma. PloS one, 21(5), e0349101. https://doi.org/10.1371/journal.pone.0349101

BibTeX

@article{blomberg2026overexpression, author = {Blomberg, Linnea and Raba, Leonora and Bengzon, Johan and Osther, Kurt and Nittby Redebrandt, Henrietta}, title = {{Overexpression of key complement regulators in glioblastoma}}, journal = {PloS one}, year = {2026}, month = may, volume = {21}, number = {5}, pages = {e0349101}, publisher = {PLOS}, issn = {1932-6203}, doi = {10.1371/journal.pone.0349101}, url = {https://doi.org/10.1371/journal.pone.0349101}, pmid = {42139305}, pmcid = {PMC13178988} }

RIS

TY - JOUR AU - Blomberg, Linnea AU - Raba, Leonora AU - Bengzon, Johan AU - Osther, Kurt AU - Nittby Redebrandt, Henrietta TI - Overexpression of key complement regulators in glioblastoma T2 - PloS one J2 - PLoS One PY - 2026 DA - 2026/05/15 VL - 21 IS - 5 SP - e0349101 SN - 1932-6203 PB - PLOS DO - 10.1371/journal.pone.0349101 UR - https://doi.org/10.1371/journal.pone.0349101 LA - en ER -

CSL-JSON

{ "id": "10.1371/journal.pone.0349101", "type": "article-journal", "title": "Overexpression of key complement regulators in glioblastoma", "container-title": "PloS one", "author": [ { "family": "Blomberg", "given": "Linnea" }, { "family": "Raba", "given": "Leonora" }, { "family": "Bengzon", "given": "Johan" }, { "family": "Osther", "given": "Kurt" }, { "family": "Nittby Redebrandt", "given": "Henrietta" } ], "container-title-short": "PLoS One", "volume": "21", "issue": "5", "page": "e0349101", "DOI": "10.1371/journal.pone.0349101", "PMID": "42139305", "PMCID": "PMC13178988", "ISSN": "1932-6203", "publisher": "PLOS", "URL": "https://doi.org/10.1371/journal.pone.0349101", "language": "en", "issued": { "date-parts": [ [ 2026, 5, 15 ] ] } }

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.